The TAND checklist: a useful screening tool in children with tuberous sclerosis and neurofibromatosis type 1.


Journal

Orphanet journal of rare diseases
ISSN: 1750-1172
Titre abrégé: Orphanet J Rare Dis
Pays: England
ID NLM: 101266602

Informations de publication

Date de publication:
07 09 2020
Historique:
received: 31 12 2019
accepted: 03 08 2020
entrez: 7 9 2020
pubmed: 8 9 2020
medline: 22 6 2021
Statut: epublish

Résumé

Tuberous Sclerosis Complex (TSC) and Neurofibromatosis type 1 (NF1) are neurocutaneous disorders commonly characterized by neuropsychiatric comorbidities. The TAND (Tuberous Sclerosis Associated Neuropsychiatric Disorders) Checklist is currently used to quickly screen for behavioural, psychiatric, intellectual, academic, neuropsychological and psychosocial manifestations in patients with TSC. We administered the authorized Italian version of the TAND Checklist to the parents of 42 TSC patients and 42 age- and sex-matched NF1 patients, for a total of 84 individuals, aged 4-20 years. Aims of this study: - to test the overall usability of the TAND Checklist in NF1, -to compare the results between children and adolescents with TSC and NF1, and -to examine the association between neuropsychiatric manifestations and severity of the phenotype in terms of epilepsy severity in the TSC cohort and disease severity according to the modified version of the Riccardi severity scale in the NF1 cohort. TSC cohort: 35.6% had Intellectual Disability (ID), 11.9% Specific Learning Disorders (SLD), 50.0% Attention Deficit Hyperactivity Disorder (ADHD) and 16.6% anxious/mood disorder. 33.3% had a formal diagnosis of Autism Spectrum Disorder (ASD). Paying attention and concentrating (61.9%), impulsivity (54.8%), temper tantrums (54.8%), anxiety (45.2%), overactivity/hyperactivity (40.5%), aggressive outburst (40.5%), absent or delayed onset of language (40.5%), repetitive behaviors (35.7%), academic difficulties (> 40%), deficits in attention (61.9%) and executive skills (50.0%) were the most commonly reported problems. NF1 cohort: 9.5% had ID, 21.4% SLD, 46.6% ADHD, and 33.3% anxious/mood disorder. No one had a diagnosis of ASD. Commonly reported issues were paying attention and concentrating (59.5%), impulsivity (52.4%), anxiety (50.0%), overactivity/hyperactivity (38.1%), temper tantrums (38.1%), academic difficulties (> 40%), deficits in attention (59.5%), and executive skills (38.1%). Neuropsychiatric features in TSC vs NF1: Aggressive outburst and ASD features were reported significantly more frequently in TSC than in NF1. Neuropsychiatric manifestations and phenotype severity: Depressed mood, absent or delayed onset of language, repetitive language, difficulties in relationship with peers, repetitive behaviors, spelling, mathematics, dual-tasking, visuo-spatial tasks, executive skills, and getting disoriented were significantly different among TSC patients with different epilepsy severity. No statistically significant differences in the NF1 subgroups were noted for any of the items in the checklist. The TAND Checklist used for TSC is acceptable and feasible to complete in a clinical setting, and is able to detect the complexity of neuropsychiatric involvement in NF1 as well. NF1 is mainly characterized by an ADHD profile, anxiety problems and SLD, while ASD features are strongly associated with TSC. In conclusion, the TAND Checklist is a useful and feasible screening tool, in both TSC and NF1.

Sections du résumé

BACKGROUND
Tuberous Sclerosis Complex (TSC) and Neurofibromatosis type 1 (NF1) are neurocutaneous disorders commonly characterized by neuropsychiatric comorbidities. The TAND (Tuberous Sclerosis Associated Neuropsychiatric Disorders) Checklist is currently used to quickly screen for behavioural, psychiatric, intellectual, academic, neuropsychological and psychosocial manifestations in patients with TSC. We administered the authorized Italian version of the TAND Checklist to the parents of 42 TSC patients and 42 age- and sex-matched NF1 patients, for a total of 84 individuals, aged 4-20 years. Aims of this study: - to test the overall usability of the TAND Checklist in NF1, -to compare the results between children and adolescents with TSC and NF1, and -to examine the association between neuropsychiatric manifestations and severity of the phenotype in terms of epilepsy severity in the TSC cohort and disease severity according to the modified version of the Riccardi severity scale in the NF1 cohort.
RESULTS
TSC cohort: 35.6% had Intellectual Disability (ID), 11.9% Specific Learning Disorders (SLD), 50.0% Attention Deficit Hyperactivity Disorder (ADHD) and 16.6% anxious/mood disorder. 33.3% had a formal diagnosis of Autism Spectrum Disorder (ASD). Paying attention and concentrating (61.9%), impulsivity (54.8%), temper tantrums (54.8%), anxiety (45.2%), overactivity/hyperactivity (40.5%), aggressive outburst (40.5%), absent or delayed onset of language (40.5%), repetitive behaviors (35.7%), academic difficulties (> 40%), deficits in attention (61.9%) and executive skills (50.0%) were the most commonly reported problems. NF1 cohort: 9.5% had ID, 21.4% SLD, 46.6% ADHD, and 33.3% anxious/mood disorder. No one had a diagnosis of ASD. Commonly reported issues were paying attention and concentrating (59.5%), impulsivity (52.4%), anxiety (50.0%), overactivity/hyperactivity (38.1%), temper tantrums (38.1%), academic difficulties (> 40%), deficits in attention (59.5%), and executive skills (38.1%). Neuropsychiatric features in TSC vs NF1: Aggressive outburst and ASD features were reported significantly more frequently in TSC than in NF1. Neuropsychiatric manifestations and phenotype severity: Depressed mood, absent or delayed onset of language, repetitive language, difficulties in relationship with peers, repetitive behaviors, spelling, mathematics, dual-tasking, visuo-spatial tasks, executive skills, and getting disoriented were significantly different among TSC patients with different epilepsy severity. No statistically significant differences in the NF1 subgroups were noted for any of the items in the checklist.
CONCLUSION
The TAND Checklist used for TSC is acceptable and feasible to complete in a clinical setting, and is able to detect the complexity of neuropsychiatric involvement in NF1 as well. NF1 is mainly characterized by an ADHD profile, anxiety problems and SLD, while ASD features are strongly associated with TSC. In conclusion, the TAND Checklist is a useful and feasible screening tool, in both TSC and NF1.

Identifiants

pubmed: 32894194
doi: 10.1186/s13023-020-01488-4
pii: 10.1186/s13023-020-01488-4
pmc: PMC7487732
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

237

Références

J Neurodev Disord. 2014;6(1):10
pubmed: 24822087
Orphanet J Rare Dis. 2018 Sep 10;13(1):157
pubmed: 30201051
Pediatr Rev. 2017 Mar;38(3):119-128
pubmed: 28250072
Dev Med Child Neurol. 2013 Feb;55(2):111-25
pubmed: 22934576
Am J Med Genet B Neuropsychiatr Genet. 2018 Apr;177(3):319-328
pubmed: 29243874
J Genet Couns. 2018 Feb;27(1):115-123
pubmed: 28735371
Orphanet J Rare Dis. 2015 Dec 02;10:154
pubmed: 26631248
Annu Rev Genomics Hum Genet. 2017 Aug 31;18:115-142
pubmed: 28859574
Behav Neurol. 2019 Jan 13;2019:7146168
pubmed: 30733835
Trends Biochem Sci. 2011 Jun;36(6):320-8
pubmed: 21531565
Am J Med Genet B Neuropsychiatr Genet. 2012 Oct;159B(7):869-73
pubmed: 22911924
Orphanet J Rare Dis. 2017 Jan 5;12(1):2
pubmed: 28057044
Semin Pediatr Neurol. 1998 Dec;5(4):276-86
pubmed: 9874855
Dev Med Child Neurol. 2013 Feb;55(2):139-45
pubmed: 23163236
Dev Med Child Neurol. 2017 Nov;59(11):1112-1116
pubmed: 28845518
J Intellect Disabil Res. 2008 Apr;52(Pt 4):348-57
pubmed: 18179508
J Pediatr. 2006 Sep;149(3):348-53
pubmed: 16939745
Dev Med Child Neurol. 2019 Aug;61(8):972-978
pubmed: 30659594
J Child Neurol. 2017 Mar;32(4):387-396
pubmed: 28193119
Dev Med Child Neurol. 2012 Oct;54(10):898-904
pubmed: 22845611
Semin Pediatr Neurol. 2006 Mar;13(1):8-20
pubmed: 16818171
Pediatr Neurol. 2015 Jan;52(1):16-24
pubmed: 25499093
Dev Med Child Neurol. 2013 Feb;55(2):131-8
pubmed: 23163951
Dev Neuropsychol. 2012;37(7):590-600
pubmed: 23066937
Pediatr Neurol. 2013 Oct;49(4):243-54
pubmed: 24053982
Lancet Neurol. 2015 Jul;14(7):733-45
pubmed: 26067126
Pediatr Neurol. 2015 Jan;52(1):25-35
pubmed: 25532776
Ment Retard Dev Disabil Res Rev. 2000;6(2):117-24
pubmed: 10899804
Dev Med Child Neurol. 2013 Feb;55(2):146-53
pubmed: 23205844
Psychol Med. 2015 Aug;45(11):2321-31
pubmed: 25827976
Am J Med Genet C Semin Med Genet. 2018 Sep;178(3):309-320
pubmed: 30117265
Dev Med Child Neurol. 2015 Jul;57(7):645-651
pubmed: 29927487
Epilepsia Open. 2018 Dec 21;4(1):73-84
pubmed: 30868117
Dev Med Child Neurol. 2012 Oct;54(10):892-7
pubmed: 22881119
Dev Med Child Neurol. 2019 Feb;61(2):168-173
pubmed: 30298907
Neurology. 2016 Aug 16;87(7 Suppl 1):S21-30
pubmed: 27527646
Epilepsy Behav. 2016 Jul;60:63-67
pubmed: 27179194
Pediatr Neurol. 2013 Oct;49(4):255-65
pubmed: 24053983
Am J Med Genet A. 2007 Oct 1;143A(19):2261-73
pubmed: 17726688
J Med Genet. 2007 Feb;44(2):81-8
pubmed: 17105749
Dev Med Child Neurol. 2006 Dec;48(12):973-7
pubmed: 17109785
Am J Med Genet C Semin Med Genet. 2018 Sep;178(3):299-308
pubmed: 30255982
J Autism Dev Disord. 2018 Jul;48(7):2278-2285
pubmed: 29423604

Auteurs

Francesca Cervi (F)

Epilepsy Center- Child Neuropsychiatry Unit, ASST Santi Paolo Carlo, Department of Health Sciences, University of Milan, Via di Rudinì 8, 20142, Milan, Italy.

Veronica Saletti (V)

Developmental Neurology Unit, Fondazione IRCCS Istituto Neurologico Carlo Besta, 20131, Milan, Italy.

Katherine Turner (K)

Epilepsy Center- Child Neuropsychiatry Unit, ASST Santi Paolo Carlo, Department of Health Sciences, University of Milan, Via di Rudinì 8, 20142, Milan, Italy.

Angela Peron (A)

Epilepsy Center- Child Neuropsychiatry Unit, ASST Santi Paolo Carlo, Department of Health Sciences, University of Milan, Via di Rudinì 8, 20142, Milan, Italy. angela.peron@unimi.it.
Department of Health Sciences, University of Milan, Milan, Italy. angela.peron@unimi.it.
Department of Pediatrics, Division of Medical Genetics, University of Utah School of Medicine, Salt Lake City, UT, USA. angela.peron@unimi.it.

Sara Bulgheroni (S)

Developmental Neurology Unit, Fondazione IRCCS Istituto Neurologico Carlo Besta, 20131, Milan, Italy.

Matilde Taddei (M)

Developmental Neurology Unit, Fondazione IRCCS Istituto Neurologico Carlo Besta, 20131, Milan, Italy.

Francesca La Briola (F)

Epilepsy Center- Child Neuropsychiatry Unit, ASST Santi Paolo Carlo, Department of Health Sciences, University of Milan, Via di Rudinì 8, 20142, Milan, Italy.

Maria Paola Canevini (MP)

Epilepsy Center- Child Neuropsychiatry Unit, ASST Santi Paolo Carlo, Department of Health Sciences, University of Milan, Via di Rudinì 8, 20142, Milan, Italy.
Department of Health Sciences, University of Milan, Milan, Italy.

Aglaia Vignoli (A)

Epilepsy Center- Child Neuropsychiatry Unit, ASST Santi Paolo Carlo, Department of Health Sciences, University of Milan, Via di Rudinì 8, 20142, Milan, Italy.
Department of Health Sciences, University of Milan, Milan, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH